CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYER POSITIONING, 2017
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Growth in incidence of cardiac disorders
3.5.1.2. Increase in geriatric population
3.5.1.3. Rise in patient awareness

3.5.2. Restraints

3.5.2.1. Limited insurance coverage and high cost of devices

3.5.3. Opportunities

3.5.3.1. Improvement in healthcare infrastructure in emerging nations

CHAPTER 4 STROKE MANAGEMENT MARKET, BY TYPE

4.1. OVERVIEW
4.2. DIAGNOSTICS

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Computed tomography scan (CT Scan)

4.2.3.1. Market size and forecast

4.2.4. Magnetic resonance imaging (MRI)

4.2.4.1. Market size and forecast

4.2.5. Carotid ultrasound

4.2.5.1. Market size and forecast

4.2.6. Cerebral angiography

4.2.6.1. Market size and forecast

4.2.7. Electrocardiography

4.2.7.1. Market size and forecast

4.2.8. Echocardiography

4.2.8.1. Market size and forecast

4.2.9. Other diagnostics

4.2.9.1. Market size and forecast

4.3. THERAPEUTICS

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Tissue plasminogen activator

4.3.3.1. Market size and forecast

4.3.4. Anticoagulant

4.3.4.1. Market size and forecast

4.3.5. Antiplatelet

4.3.5.1. Market size and forecast

4.3.6. Antihypertensive

4.3.6.1. Market size and forecast

CHAPTER 5 STROKE MANAGEMENT MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ISCHEMIC STROKE

5.2.1. Market size and forecast

5.3. HEMORRHAGIC STROKE

5.3.1. Market size and forecast

CHAPTER 6 STROKE MANAGEMENT MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends and opportunities
6.2.2. Market size and forecast
6.2.3. U.S. market size and forecast
6.2.4. Canada market size and forecast
6.2.5. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends and opportunities
6.3.2. Market size and forecast
6.3.3. Germany market size and forecast
6.3.4. France market size and forecast
6.3.5. UK market size and forecast
6.3.6. Italy market size and forecast
6.3.7. Spain market size and forecast
6.3.8. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends and opportunities
6.4.2. Market size and forecast
6.4.3. Japan market size and forecast
6.4.4. China market size and forecast
6.4.5. Australia market size and forecast
6.4.6. India market size and forecast
6.4.7. South Korea market size and forecast
6.4.8. Taiwan market size and forecast
6.4.9. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends and opportunities
6.5.2. Market size and forecast
6.5.3. Brazil market size and forecast
6.5.4. Turkey market size and forecast
6.5.5. Saudi Arabia market size and forecast
6.5.6. South Africa market size and forecast
6.5.7. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. B. BRAUN MELSUNGEN AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. BOSTON SCIENTIFIC CORPORATION

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. BRISTOL-MYERS SQUIBB COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. CARDINAL HEALTH, INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. GLAXOSMITHKLINE PLC

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. MEDTRONIC PLC

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. MERCK & CO., INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. SIEMENS AKTIENGESELLSCHAFT (SIEMENS HEALTHCARE)

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments